The Patient-Reported Outcomes, Community Engagement, and Language (PRO-CEL) Core enhances the objectives of the Center's research programs by supporting the array of MSK investigators who wish to capture self-reported information from culturally diverse patients, caregivers, clinical staff, and community members. The faculty of the PRO-CEL Core are nationally recognized social, behavioral sciences, and community-engagement experts who provide technical assistance to all users throughout their various stages of research, including grant and protocol development, research study assistant and support staff training, and result dissemination. The PRO-CEL Core aims to 1) provide expert consultation with respect to selection, analysis, and interpretation of psychometrically sound patient-reported outcomes (PROs) or other self-report instruments for the capture of health-related quality of life (HRQoL), health behavior change, symptom control, treatment-related adverse events (AEs), and quality of care; 2) support qualitative interview, focus group, and other observational research methodology for generating new testable hypotheses, developing novel assessment tools, and establishing cultural and linguistic equivalency of PRO measures; 3) provide pre-review and feedback of peer-reviewed funding applications consistent with ?best practices? in psychosocial, behavioral, and community-engaged oncology research, including culturally and linguistically responsive research; 4) assist with the creation of online surveys for data capture; and 5) provide methodological support for clinical trial, behavioral, and population-based research that seeks to engage community or minority populations. The services provided by the PRO-CEL Core have supported the research of 105 MSK investigators in the past year, and during the past grant period, the work of this Core has contributed to 397 peer-reviewed publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084832
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Hsin, Jing-Ping; Lu, Yuheng; Loeb, Gabriel B et al. (2018) The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types. Nat Immunol 19:1137-1145
Senders, Max L; Hernot, Sophie; Carlucci, Giuseppe et al. (2018) Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. JACC Cardiovasc Imaging :
Rogers, Emma M; Connolly, Karen L; Nehal, Kishwer S et al. (2018) Comorbidity scores associated with limited life expectancy in the very elderly with nonmelanoma skin cancer. J Am Acad Dermatol 78:1119-1124
Flinn, Ian W; O'Brien, Susan; Kahl, Brad et al. (2018) Duvelisib, a novel oral dual inhibitor of PI3K-?,?, is clinically active in advanced hematologic malignancies. Blood 131:877-887
Gay, Hiram A; Oh, Jung Hun; Apte, Aditya P et al. (2018) Predictors of acute throat or esophageal patient reported pain during radiation therapy for head and neck cancer. Clin Transl Radiat Oncol 13:1-6
Touijer, Karim A; Karnes, Robert Jeffery; Passoni, Niccolo et al. (2018) Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol 73:890-896
Pianko, Matthew J; Moskowitz, Alison J; Lesokhin, Alexander M (2018) Immunotherapy of Lymphoma and Myeloma: Facts and Hopes. Clin Cancer Res 24:1002-1010
Bucciarelli, Peter R; Tan, Kay See; Chudgar, Neel P et al. (2018) BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis. J Thorac Oncol 13:73-84
Yang, Annie; Baxi, Shrujal; Korenstein, Deborah (2018) ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors. J Oncol Pract 14:72-76
Mikropoulos, Christos; Selkirk, Christina G Hutten; Saya, Sibel et al. (2018) Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer 118:266-276

Showing the most recent 10 out of 8799 publications